

HEALTH ADVISORY



Public Health
Prevent. Promote. Protect.

Region 4 Public Health
Clark, Cowlitz, Skamania, Wahkiakum
counties, and Cowlitz Tribe

To: Physicians and other health care providers

Please distribute a copy of this information to each provider in your organization.

Questions regarding this information may be directed to the following Region 4 health officers:

Alan Melnick, MD, MPH, CPH

Clark County Public Health, 564.397.8182

Skamania County Community Health, 509.427.3850

Cowlitz County Health & Human Services, 360.414.5599

Wahkiakum County Health & Human Services, 360.795.6207

Steven Krager, MD, MPH

Clark County Public Health, 564.397.8182

Skamania County Community Health, 509.427.3850

Cowlitz County Health & Human Services, 360.414.5599

Wahkiakum County Health & Human Services, 360.795.6207

Alert categories:

Health Alert: conveys the highest level of importance; warrants immediate action or attention.

Health Advisory: provides important information for a specific incident or situation; may not require immediate action.

Health Update: provides updated information regarding an incident or situation; no immediate action necessary.

FDA announces Evusheld is not currently authorized for emergency use in the US



Summary

The US Food and Drug Administration (FDA) revised the emergency use authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) on Jan. 26, 2023 to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%.

Based on this revision to the EUA, **Evusheld is not currently authorized for use in the US until further notice by the FDA.** There are several treatments – Paxlovid, Veklury (remdesivir) and Lagevrio (molnupiravir) – that are expected to work against currently circulating variants and are authorized or approved to treat certain patients.

The FDA recommends that facilities and providers with Evusheld retain all product for potential future use.

Recommended actions

Patients who become infected with SARS-CoV-2 and develop symptoms of COVID-19 should seek medical attention, including starting treatment for COVID-19 as appropriate.

There are [several treatments](#) – Paxlovid, Veklury (remdesivir) and Lagevrio (molnupiravir) – that are expected to work against currently circulating variants and are authorized or approved to treat certain patients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease, including hospitalization or death. Healthcare providers should assess whether treatments are right for their patients.

The FDA recommends that facilities and providers with Evusheld retain all product in the event that SARS-CoV-2 variants which are neutralized by Evusheld become more prevalent in the U.S. in the future. Retained product must be appropriately held in accordance with storage conditions detailed in the authorized [Fact Sheet for Healthcare Providers](#) and the [Letter of Authorization](#).

Background

Data show Evusheld is unlikely to be active against certain SARS-CoV-2 variants. According to the most recent Centers for Disease Control and Prevention [Nowcast data](#), these variants are projected to be responsible for more than 90% of current infections in the US. This means Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants.

Limiting the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions that can be potentially serious, at a time when fewer than 10% of circulating variants in the US causing infection are susceptible to the product.

The FDA will continue to work with the Administration for Strategic Preparedness and Response, the CDC, and the National Institutes of Health on surveillance of variants that may impact the use of the therapies authorized for emergency use. The FDA will consider additional action as new information becomes available and provide further updates on the [FDA's website](#).

Thank you for your partnership.

Local health jurisdiction	Phone	Fax
Clark County Public Health	564.397.8182	564.397.8080
Cowlitz County Health & Human Services	360.414.5599	360.425.7531
Skamania County Community Health	509.427.3850	509.427.0188
Wahkiakum County Health and Human Services	360.795.6207	360.795.6143